Registry and clinical study for Wolfram syndrome and related disorders
Official title: Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Run by Washington University School of Medicine · NCT02841553 · Data updated 2026-11-12
This study is trying to gather information from people with Wolfram syndrome to better understand the condition and its effects, while also looking for specific gene mutations.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Status | Recruiting |
| Started | July 2011 |
| Main results expected | April 2027 |
| Study ends | April 2027 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT02841553 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with Wolfram syndrome, including minors, who have access to the Internet.
✕Probably not a fit
Patients without a diagnosis of Wolfram syndrome or those who do not meet the eligibility criteria will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish and maintain an international registry of patients diagnosed with Wolfram syndrome, focusing on collecting clinical information to better understand the natural history and metabolic phenotypes associated with the condition. Participants will provide blood samples for genetic analysis to identify mutations in the WFS1 gene, which is linked to the syndrome. The study will analyze data on the onset and progression of symptoms such as diabetes mellitus, optic nerve atrophy, and other related complications. The findings may offer insights into the complexities of diabetes and related disorders.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Wolfram syndrome and improve management strategies for patients with diabetes and related conditions.
How similar studies have gone: While the approach of establishing a registry for rare genetic disorders is not novel, the specific focus on Wolfram syndrome and its genetic underpinnings is relatively unique and may provide new insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Any patient worldwide with a diagnosis of Wolfram syndrome and with access to the Internet can be enrolled in the Registry. Since the disease usually manifests in the first decade of life and tends to have an inevitably progressive course, participation of minors is important for establishing the natural course of the disease. Inclusion Criteria: Major Criteria * Diabetes mellitus \<16 yrs * Optic atrophy \<16 yrs Minor Criteria * Diabetes insipidus * Diabetes mellitus \>16yrs * Optic atrophy \>16 yrs * Sensorineural deafness * Neurological signs (ataxia, epilepsy, cognitive impairment) * Renal tract abnormalities (structural or functional) * 1 loss of function mutation in WFS1/CISD2 AND/OR family history of Wolfram syndrome Minimum Required * 2 major OR * 1 major plus 2 minor criteria OR * 2 pathological WFS1 or CISD2 mutations are identified Other variable suggestive evidence * Hypogonadism (males) * An absence of type 1 diabetes auto-antibodies * Bilateral cataracts * Psychiatric disorder * Gastrointestinal Exclusion Criteria: Inability of a patient and/or a guardian to obtain help with translation and thus, inability to understand questionnaire. Parent, Sibs, and Spouses: \- Parents, sibs, and spouses that are unaffected will be recruited as controls. Inclusion criterion is having the unaffected status and exclusion criterion is if the person cannot understand the Informed Consent Document.
Where it's running
-
Washington University School of Medicine
St Louis, Missouri, United States Recruiting
Study contacts
- Study coordinator: Fumihiko Urano, MD
- Email: wolframsyndrome@wustl.edu
- Phone: (314) 477-1527
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman
A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
-
SugarVita 2.0: a 12-week digital game for adults with type 2 diabetes
This 12-week pilot tests SugarVita 2.0, a serious digital game, to see if it helps adults with type 2 diabetes manage their condition and feel more confident.
-
Linking social care with healthcare to help manage chronic diseases
This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.
-
Transcutaneous and topical photobiomodulation for diabetic foot ulcers
This phase 2 trial tests whether combining transcutaneous and topical photobiomodulation helps heal foot ulcers in adults with diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.